TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.

Snežana MilanovićNina DedicRobert LewDuane BurtonKenneth S KoblanMichael Camilleri Seth C Hopkins

Published in: Diabetes, obesity & metabolism (2024)

Ulotaront delayed the GE of solids in patients with schizophrenia and concurrent MetS with prediabetes. Additional studies are needed to assess whether treatment with TAAR1 agonists is associated with weight loss and glucoregulatory improvement.

Keyphrases

metabolic syndrome
weight loss
locally advanced
bariatric surgery
uric acid
insulin resistance
roux en y gastric bypass
squamous cell carcinoma
cardiovascular disease
case control
replacement therapy